


Fig. 1a




Fig. 1b




Fig. 2a




Fig. 2b



Penetration of MC903 into skin at different time points
% of applied dose
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
MC903 (Daivobet® Ointment, 2h)
MC903 (Daivobet® Ointment, 6h)
MC903 (Daivobet® Ointment, 21h)
MC903 (Spray TG403/5E1, 2h)
MC903 (Spray TG403/5E1, 6h)
MC903 (Spray TG403/5E1, 21h)
Receptor fluid
Applied skin

Fig. 3



Penetration of BDP into skin at different time points
% of applied dose
0
2
4
6
8
10
12
14
BDP (Daivobet® Ointment, 2h)
BDP (Daivobet® Ointment, 6h)
BDP (Daivobet® Ointment, 21h)
BDP (Spray TG403/5E1, 2h)
BDP (Spray TG403/5E1, 6h)
BDP (Spray TG403/5E1, 21h)
Receptor fluid
Applied skin

Fig. 4




Fig. 5




Fig. 6a




Fig. 6b




Fig. 7